Acid‐Responsive Transferrin Dissociation and GLUT Mediated Exocytosis for Increased Blood–Brain Barrier Transcytosis and Programmed Glioma Targeting Delivery
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Receptor mediated transcytosis (RMT) is a common mechanism used for nanotherapeutics to traverse the blood–brain barrier (BBB). However, the transcytosis of ligand modified nanoparticles via RMT is likely to be trapped within brain capillary endothelial cells due to the high binding affinity of ligand with receptors, which greatly reduces the amount of nanoparticles across BBB. Here, P‐aminophenyl‐α‐D‐mannopyranoside (MAN) decorated doxorubicin‐loaded dendrigraft poly‐l‐lysine with acid‐cleavable transferrin (Tf) coating outside (DD‐MCT) is proposed. The DD‐MCT is engineered to specifically recognize the Tf receptor (TfR) on the luminal side of BBB endothelium. Then the DD‐MCT undergoes an acid‐responsive cleavage of Tf, leading to the separation of MAN‐decorated DGL‐DOX (DD‐M) from the Tf–TfR complex in endo/lysosomes. The detached DD‐M is more prone to escape from endo/lysosomes and can further be exocytosed into brain parenchyma via the mediation of glucose transporter located on the abluminal endothelial membrane. Moreover, the DD‐M in brain parenchyma can target glioma cells. Significantly, the DD‐MCT enters into brain parenchyma in greater amounts, resulting in enhanced accumulation at glioma site and thus improved antiglioma therapeutic outcome. This strategy pioneers a new path for reducing the trapping of nanotherapeutics within BBB endothelium but increasing their transcytosis into brain parenchyma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
Transferrin receptor on endothelium of brain capillaries
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984) · Nature · doi:10.1038/312162a0 · Cited by 1,061
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
Wang, F., Wang, Y.-C., Dou, S., Xiong, M.-H., Sun, T.-M., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn200007z · Cited by 813
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
“172,173 For example, acid-sensitive imine linker (DAK) was conjugated with D-T7 peptide on the nanoparticle surface, which would break up in acidic environment, facilitating the endo/lysosomal escape.”
BackgroundPolymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
Self-citationSize-Tunable Strategies for a Tumor Targeted Drug Delivery System
Yu, W., Liu, R., Zhou, Y., & Gao, H. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b01139 · Cited by 489
Self-citationHan, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358
Israel, L. L., Galstyan, A., Holler, E., & Ljubimova, J. Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.009 · Cited by 337
Wang, J., Tang, W., Yang, M., Yin, Y., Li, H., Hu, F., Tang, L., Ma, X., Zhang, Y., & Wang, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120784 · Cited by 317
The blood–tumour barrier in cancer biology and therapy
Steeg, P. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00529-6 · Cited by 287
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Xiao, W., & Gao, H. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.011 · Cited by 256
Self-citationSmart drug delivery systems for precise cancer therapy
Wang, X., Li, C., Wang, Y., Chen, H., Zhang, X., Luo, C., Zhou, W., Li, L., Teng, L., Yu, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.013 · Cited by 233
Dendrimer-Based Drug Delivery Systems for Brain Targeting
Zhu, Y., Liu, C., & Pang, Z. (2019) · Biomolecules · doi:10.3390/biom9120790 · Cited by 220
“Significantly, DD-MCT transport into brain tumors was greatly enhanced, resulting in improved anti-glioma therapeutic outcome [136].”
BackgroundMethodInfluentialZhou, Y., Chen, X., Cao, J., & Gao, H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00649a · Cited by 213
Self-citationXiao, W., Wang, Y., Zhang, H., Liu, Y., Xie, R., He, X., Zhou, Y., Liang, L., & Gao, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120888 · Cited by 174
Self-citationPeng, L.-H., Wang, M.-Z., Chu, Y., Zhang, L., Niu, J., Shao, H.-T., Yuan, T.-J., Jiang, Z.-H., Gao, J.-Q., & Ning, X.-H. (2020) · Science Advances · doi:10.1126/sciadv.aba2735 · Cited by 177
“It was reported that higher binding affinity of ligands to receptors may decrease the transcytosis of nanoparticles through blood-brain barrier (BBB) ( 17 ), which might be the result of BBB being made up of a network of high-density cells tightly joined together to form an almost impermeable layer.”
The impact of protein corona on the biological behavior of targeting nanomedicines
Farshbaf, M., Valizadeh, H., Panahi, Y., Fatahi, Y., Chen, M., Zarebkohan, A., & Gao, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121458 · Cited by 95
Self-citationEnhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
“…cancer cell line (Dixit et al., 2015) TfR Dendrigraft poly-L-Lysine Tf Doxorubicin Glioblasto(Aguilera et al., 2019; Hatamluyi & Es'haghi, 2017)ma (Ruan et al., 2018) TfR Immunoliposome Transferrin receptor antibody (OX26) Oxaliplatin Blood-Brain Barrier (BBB) (Johnsen et al., 2017) TfR…”
BackgroundHe, X., Wang, X., Yang, L., Yang, Z., Yu, W., Wang, Y., Liu, R., Chen, M., & Gao, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.001 · Cited by 89
Self-citationMiao, T., Ju, X., Zhu, Q., Wang, Y., Guo, Q., Sun, T., Lu, C., & Han, L. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201900259 · Cited by 70
Unmasking CSF protein corona: Effect on targeting capacity of nanoparticles
Wang, Y., Zhang, H., Xiao, W., Liu, Y., Zhou, Y., He, X., Xia, X., Gong, T., Wang, L., & Gao, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.001 · Cited by 48
Self-citationIncreased brain uptake of pterostilbene loaded folate modified micellar delivery system
Wang, Y., Su, Y., Yang, Y., Jin, H., Wu, M., Wang, Q., Sun, P., Zhang, J., Yang, X., & Shu, X. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2126559 · Cited by 25
“Huile Gao group reported that the strong binding affinity of ligand with receptors could inhibit the transcytosis through BBB and the cleavable ligand modification could improve the targeting delivery efficiency (Ruan et al., 2018; Lei et al., 2021; He et al., 2022).”
Background
Metadata
- Authors
- Ruan, S., Qin, L., Xiao, W., Hu, C., Zhou, Y., Wang, R., Sun, X., Yu, W., He, Q., & Gao, H.
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2018-05-28
- Volume
- 28
- Issue
- 30
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W2805421262
- Cited by
- 154
- References
- 16
- FWCI
- 4.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.